First in man study of EP217609, a new long-acting, neutralisable parenteral antithrombotic with a dual mechanism of action.

Summary EP217609 is a parenteral antithrombotic compound combining in one molecule an indirect anti-factor Xa inhibitor, a direct thrombin active site inhibitor and a biotin moiety.